2022 Annual Meeting Virtual Experience | ITU.4 - Industry Therapeutic Update from Novartis Gene Therapies: A New Frontier for Neurologic Disorders: Spotlight on Gene Therapy

Date Sunday 04/24/22

Time 08:00 AM - 06:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives Presentations will briefly reflect on the history and evolution of gene therapy, including the characteristics of adeno-associated virus (AAV) as a vector. The potential of gene therapy will be explored through the expanding evidence from animal and human studies supporting effective biodistribution and expression at target tissues, including the central nervous system. The speakers will finally reflect on the clinical outlook and applications of gene therapy in the landscape of neurologic disorders. ; Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
08:00 AM - 09:00 AM EDT	Speaker	Industry Therapeutic Update from Novartis Gene Therapies: A New Frontier for Neurologic Disorders: Spotlight on Gene Therapy Sandra P. Reyna, MD, John C. Kincaid, MD, FAAN, Arthur H. Burghes, MD, Bryan McGill, MD, PhD

Faculty Disclosures
Sandra P. Reyna, MD	Dr. Reyna has received personal compensation for serving as an employee of Novartis Gene Therapies.
John C. Kincaid, MD, FAAN	Dr. Kincaid has received personal compensation in the range of $500-$4,999 for serving as a Consultant for strongbridge pharmaceuticals. Dr. Kincaid has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for social security administrstion. The institution of Dr. Kincaid has received research support from Ionis Pharmaceuticals. Dr. Kincaid has received publishing royalties from a publication relating to health care. Dr. Kincaid has received personal compensation in the range of $500-$4,999 for serving as a medical expert for disability cases with social security administrstion. Dr. Kincaid has a non-compensated relationship as a I am the historian of the Board of Directors for this organization with AANEM that is relevant to AAN interests or activities.
Arthur H. Burghes, MD	No disclosure on file
Bryan McGill, MD, PhD	Dr. McGill has received personal compensation for serving as an employee of Novartis. Dr. McGill has received personal compensation for serving as an employee of AveXis. Dr. McGill has received stock or an ownership interest from Novartis.